Is MXE legal in Saudi Arabia?

Legal status

MXE is a controlled psychotropic substance in Saudi Arabia, placed at Schedule II Category B of the schedules attached to the Law of Combating Narcotics and Psychotropic Substances, Royal Decree M/39 of 1426 AH, in the version of those schedules issued on 4 September 2026. The schedule prints «MXE (methoxetamine)» in Latin script under the heading «فئة (ب):... المؤثرات العقلية», Category B psychotropic substances. That is a direct methoxetamine entry, naming both the abbreviation and the chemical name. It is worth being explicit that this is not the 3-MeO-PCP entry, because a different chemical name in a different Gulf schedule was misread that way in an earlier pass on another country, and reading an arylcyclohexylamine entry as covering every other one is exactly the error that produces a confident wrong answer. Ketamine is separately at Schedule II Category E and 2-FDCK at Category B. M/39 Articles 1 and 70 to 71 are cited for identification and for keeping the attached schedules current.

Consequences if caught

A Schedule II Category B placement brings MXE inside Article 37(I), and that article states no quantity at all. There is no weight threshold in it: the conduct named is smuggling, receipt from a smuggler, and import, export, manufacture, production, extraction or cultivation with intent to promote, together with the repeat promotion histories the article sets out. Death under Article 37(I) is a statutory ta'zir penalty and it is not mandatory, because Article 37(II) gives the court the power to reduce it; where the court does reduce, the substitute is a prison term of not less than fifteen years with the lashes and the fine the article states. No express life imprisonment wording was found anywhere in M/39. Articles 38 to 41 are cited as the tiers below Article 37 for this placement. One feature of this row is worth stating because it is what makes the placement safe to rely on: the Category B entry is printed in Latin script as «MXE (methoxetamine)» rather than transliterated into Arabic as the neighbouring entries are, so the substance is named directly and no analogue reasoning is doing any work. It is also not the 3-MeO-PCP chemical name, which is a different compound and which produced a misreading in another jurisdiction in this corpus.

If prescribed or medical

The Saudi traveller rule is a permit rule rather than a prescription rule. A controlled medicine may be brought in only under a clearance obtained from the SFDA before travel through its Controlled Drugs System, and that advance electronic clearance is required rather than optional. MXE sits inside that regime as a Schedule II Category B substance, and no Saudi dispensing route and no medicinal product containing it was recorded, so nothing here should be read as saying a clearance would issue for it. MXE has no licensed medical use anywhere, so there is no prescription on which an application could rest.

Documentation

There is nothing to carry for this substance, because no lawful import route was established for it, and a research chemical description on an invoice is not a permission. For any controlled medicine, apply through the SFDA Controlled Drugs System before travelling, carry the clearance and not the prescription alone, bring the medicine in its original dispensing packaging with the prescription and a medical report translated into Arabic and dated less than six months before travel, and declare it at customs; advance electronic clearance has been required since 1 November 2025. The permit mechanics stated here are the SFDA traveller rules recorded on the current live cell and were not re-derived from the instrument in this pass. The Schedule II Category B placement was read in the 4 September 2026 schedules on 17 September 2026.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Saudi Arabia’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.